SEC Comment Letter for PRECIGEN, (PGEN) — Feb 10, 2026
PRECIGEN, INC.
Date: Feb. 10, 2026 · CIK: 0001356090 · Accession: 0000000000-26-001372
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-36042
Letter
February 10, 2026 Harry Thomasian Jr. Chief Financial Officer Precigen, Inc. 20374 Seneca Meadows Parkway Germantown, MD 20876 Re:Precigen, Inc. Form 10-K for the fiscal year ended December 31, 2024 Form 10-Q for the quarterly period ended September 30, 2025 File No. 001-36042 Dear Harry Thomasian Jr.: We have reviewed your January 29, 2026 response to our comment letter and have the following comment. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Unless we note otherwise, any references to prior comments are to comments in our January 29, 2026 letter. Form 10-Q for the quarterly period ended September 30, 2025 15. Segments, page 31 Please address the following regarding your response to prior comment two with a view toward ascertaining the extent to which Biopharmaceuticals and Exemplar continue to constitute two separate operating segments as defined in ASC 280-10-50-1: •Regarding the second bullet, you have told us that you have two separate components or reporting units that were not aggregated under ASC 350-20-35-33 through 35-36. You also appear to indicate that your chief operating decision maker (CODM) continues to receive at least some level of separate discrete financial information for these reporting units. Please tell us what financial information is received by the CODM, and how it changed in the first quarter of 2025 and subsequent periods. Clarify how the financial information for these reporting units is used, and how the •1.
February 10, 2026 Page 2 uses of this information changed beginning in the first quarter of 2025 and subsequent periods. •Specifically identify what, if any, information is received but not regularly used, related to these reporting units. •Explain the extent to which the information received and available to the CODM which you used for impairment testing is different than what the CODM formerly received for management and resource allocation of the operating segments. •Regarding the third bullet, you have told us that "In the first quarter of 2025, in conjunction with the February 2025 FDA approval for priority review of the Company’s PRGN-2012 product, the Company’s CODM no longer regularly reviewed separate discrete financial information for Biopharmaceuticals or Exemplar. Tell us what, if any, changes were made to your management structure that coincided with these changes to what the CODM reviews. As part of your response, identify any changes to segment managers or other personnel or financial reporting system changes. •Tell us and revise to disclose why FDA approval of priority review for PRGN-2012 triggered these changes in what the CODM reviews. Please contact Jenn Do at 202-551-3743 or Kevin Vaughn at 202-551-3494 if you have questions regarding comments on the financial statements and related matters. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
February 10, 2026
Harry Thomasian Jr.
Chief Financial Officer
Precigen, Inc.
20374 Seneca Meadows Parkway
Germantown, MD 20876
Re:Precigen, Inc.
Form 10-K for the fiscal year ended December 31, 2024
Form 10-Q for the quarterly period ended September 30, 2025
File No. 001-36042
Dear Harry Thomasian Jr.:
We have reviewed your January 29, 2026 response to our comment letter and have the
following comment.
Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this letter, we may have additional comments. Unless
we note otherwise, any references to prior comments are to comments in our January 29, 2026
letter.
Form 10-Q for the quarterly period ended September 30, 2025
15. Segments, page 31
Please address the following regarding your response to prior comment two with a view
toward ascertaining the extent to which Biopharmaceuticals and Exemplar continue to
constitute two separate operating segments as defined in ASC 280-10-50-1:
•Regarding the second bullet, you have told us that you have two separate
components or reporting units that were not aggregated under ASC 350-20-35-33
through 35-36. You also appear to indicate that your chief operating decision maker
(CODM) continues to receive at least some level of separate discrete financial
information for these reporting units. Please tell us what financial information is
received by the CODM, and how it changed in the first quarter of 2025 and
subsequent periods.
Clarify how the financial information for these reporting units is used, and how the •1.
February 10, 2026
Page 2
uses of this information changed beginning in the first quarter of 2025 and
subsequent periods.
•Specifically identify what, if any, information is received but not regularly used,
related to these reporting units.
•Explain the extent to which the information received and available to the CODM
which you used for impairment testing is different than what the CODM formerly
received for management and resource allocation of the operating segments.
•Regarding the third bullet, you have told us that "In the first quarter of 2025, in
conjunction with the February 2025 FDA approval for priority review of the
Company’s PRGN-2012 product, the Company’s CODM no longer regularly
reviewed separate discrete financial information for Biopharmaceuticals or
Exemplar. Tell us what, if any, changes were made to your management structure
that coincided with these changes to what the CODM reviews. As part of your
response, identify any changes to segment managers or other personnel or financial
reporting system changes.
•Tell us and revise to disclose why FDA approval of priority review for PRGN-2012
triggered these changes in what the CODM reviews.
Please contact Jenn Do at 202-551-3743 or Kevin Vaughn at 202-551-3494 if you have
questions regarding comments on the financial statements and related matters.
Sincerely,
Division of Corporation Finance
Office of Life Sciences